BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABL Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ABL Bio's drugs run\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07432295-10902@assetmemo.bio
DTSTAMP:20261121T005350Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:givastomig: Phase 2 readout est. (NCT07432295)
DESCRIPTION:givastomig\, phase 2\, Gastric Cancer.\nStudy: Givastomig Combi
 ned With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metas
 tatic Gastric Cancer (GIVA-2)\nEstimated primary completion: March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/givastomig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07432295
URL:https://assetmemo.bio/drug/givastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
